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Congenital afibrinogenemia is a rare coagulopathy characterized by extremely low levels of functional and immunoreactive fibrinogen in
plasma, associated with a hemorrhagic phenotype of variable severity. It is transmitted as an autosomal recessive trait and is invariantly
associated with mutations affecting 1 of the 3 fibrinogen genes (FGA, FGB, and FGG, coding for Aα, Bβ, and γ chain, respectively). Most
genetic defects causing afibrinogenemia are truncating mutations, whereas only few missense mutations (6) have been identified so far, all
located in FGB. In this study, the mutational screening of an afibrinogenemic Italian male identified the first missense mutation (Met51Arg)
in FGA leading to afibrinogenemia. The patient was a compound heterozygote for a previously described frameshift mutation (1215delT) in
the same gene. Met51Arg involves a residue located at the very beginning of the coiled-coil domain, in a region demonstrated to play a
pivotal role in hexamer formation. In-vitro expression experiments showed that Met51Arg strongly reduces secretion of hexameric
fibrinogen, whereas traces of not completely assembled trimeric intermediate were found in conditioned media. Western blot analysis on the
proband's plasma confirmed the presence in vivo of the trimeric fibrinogen, supporting the hypothesis that Met51Arg prevents the final step
of fibrinogen assembly.
© 2007 Elsevier B.V. All rights reserved.Keywords: Fibrinogen; Afibrinogenemia; Aα chain; Missense mutation; Protein ex-vivo expression1. Introduction
Fibrinogen, also known as coagulation factor I, is a plasma
glycoprotein with a central role in the haemostatic process both as
adhesion protein essential to platelet aggregation and as precursor
of insoluble fibrin that forms the haemostatic clot [1]. Moreover,
as inflammation acute-phase protein, its plasma levels rise after
injury and stress [2]. FGA, FGB, and FGG genes, clustered on⁎ Corresponding author. University of Milan Department of Biology and
Genetics for Medical Sciences Via Viotti, 3/5-20133 Milano, Italy. Tel.: +39 02
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doi:10.1016/j.bbadis.2007.04.005chromosome 4q32.1, encode the 3 chains (Aα, Bβ, and γ,
respectively) that form fibrinogen [3]. Two sets of these 3 chains
originate the 340-kDa mature hexamer, which is mainly
synthesized by hepatic parenchymal cells [4] and secreted into
the bloodstream. Circulating fibrinogen shows a trinodular
structure in which the N-terminus of each chain contributes to
constitute the central E domain, while the C-termini of the Bβ and
γ chains form the 2 lateral globular D domains. The E and the D
domains are linked by 2 coiled-coil triple helices [5].
Fibrinogen assembly is a complex process taking place in the
endoplasmic reticulum; it is thought to go through the formation
of Aα-γ and Bβ-γ dimers, followed by the addition of a third
chain giving rise to trimeric half molecules. These eventually
dimerize originating the mature hexamer [6]. The lack of 1 chain
has been demonstrated to be sufficient to prevent the assembly
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leads to the complete absence of clottable fibrinogen in plasma, is
known as congenital afibrinogenemia, a rare disease characterized
by a pattern of hemorrhagic manifestations of variable severity.
Among fibrinogen congenital abnormalities, which include
dysfibrinogenemia, hypofibrinogenemia and afibrinogenemia,
only congenital afibrinogenemia (Mendelian Inheritance in
Man no. #202400) is inherited as an autosomal recessive trait,
while hypofibrinogenemia represents in most cases the
heterozygous state of afibrinogenemia and dysfibrinogenemia
is generally transmitted as a dominant disorder [8].
Among the 43 afibrinogenemia-causing mutations described
thus far, most are point mutations leading to severe truncations
of the corresponding chain [9]. Notably, only 3 large deletions
have been described and all involve the Aα-chain gene [10–12],
while the only 6 missense mutations so far reported are all
located in the Bβ-chain gene (Gly347Arg, Leu353Arg,
Gly400Asp, Gly414Ser, Gly434Asp, Trp437Gly) [13–17].
In this study, the characterization of the first missensemutation
(Met51Arg) in the FGA gene leading to afibrinogenemia is
reported. The mutation was identified in a male patient from
Rome in compound heterozygosity with a previously identified
nonsense mutation [18].
2. Materials and methods
All family members enrolled in this study signed their consent after
receiving all the necessary information about the research.
2.1. Coagulation tests
Plasma functional fibrinogen level was measured by an assay based on fibrin
polymerization time (Laboratoire Stago, Asnières, France), whose sensitivity
was 5 mg/dL. An enzyme-linked immunosorbent assay (ELISA) (sensitivity:
0.0005 mg/dL) was used to measure the antigen fibrinogen level (normal ranges
for both assays: 160–400 mg/dL).
2.2. DNA sequence analysis
Sense and antisense primers for polymerase chain reaction (PCR)
amplification and full DNA sequencing of the FGA gene (including all introns)
were designed on the basis of the sequence deposited under GenBank accession
number M64982. Their sequences can be provided on request.
PCRs were performed on genomic DNA purified from peripheral blood using
standard protocols. PCR products, purified by ammonium-acetate precipitation,
were directly sequenced using the BigDye Terminator Cycle Sequencing Ready
Reaction Kit v3.1 (Applied Biosystems, Foster City, CA, USA) and an ABI 3100
genetic analyzer (Applied Biosystems). Additional internal primers were used
whenever necessary to complete sequencing of the amplified products. Mutation
detection was performed by Factura and Sequence Navigator software packages
(Applied Biosystems).
2.3. Site-directed mutagenesis
The mutant plasmid pRSV-Neo-Aα-Met51Arg was obtained by site-
directed mutagenesis of the pRSV-Neo-Aα plasmid using the QuickChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The mutagenic
primer couple 5′-CTTCTGGCTGCAGGAGGAAAGGGTTGATTGA-3′ and
5′-TCAATCAACCCTTTCCTCCTGCAGCCAGAAG-3′ (underlined letters
indicate the mismatch), corresponding to nucleotide positions 1752–1782
(GenBank accession number M64982) was used. The introduction of the
mutation was checked by sequencing.2.4. Cell cultures, transfections, and metabolic labeling
The African green monkey kidney cell line COS-1 was grown at 37 °C in a
humidified atmosphere of 5% CO2 and 95% air, in 10-cm dishes (cell-seeding
density: 2×106 cells/dish). Dulbecco's Modified Eagle's Medium (DMEM)
containing 10% fetal bovine serum, antibiotics (100 IU/mL penicillin and
100 μg/mL streptomycin) and glutamine (1%) was used. Semi-confluent cells
were co-transfected with equimolar quantities of pRSV-Neo-Aα-Met51Arg (or
pRSV-Neo-Aα), pRSV-Neo-Bβ, and pRSV-Neo-γ plasmids, using the
Lipofectamine 2000TM reagent (Invitrogen, Carlsbad, CA, USA) following
the manufacturer's instructions. COS-1 cells were also co-transfected with
equimolar amounts of pRSV-Neo-Aα and pRSV-Neo-γ vectors to visualize
the assembly intermediate Aα-γ dimer, and mock transfected with the
unrelated pUC18 plasmid, as negative control. Twenty-four hours after
transfection, cells were washed twice with methionine- and cysteine-free
DMEM (ICN Biomedicals, High Wycombe, Berks, United Kingdom) and
incubated for 2 and 16 h in 3 mL/dish of methionine- and cysteine-free
DMEM supplemented with 200 μCi/mL [35S]-labeled methionine and
cysteine (Translable; ICN Biomedicals), 10% dialyzed fetal bovine serum,
2 mM L-glutamine, 5 mM CaCl2, 5 mg/mL bovine serum albumin (BSA),
and 0.1 mg/mL heparin.
2.5. Immunoprecipitation and sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE)
After metabolic labeling, conditioned media were collected in tubes
containing a protease inhibitor mixture (Complete; Roche, Basel, Switzerland)
and centrifuged to remove cell debris. Cells were washed 3 times with pre-
chilled PBS (phosphate buffered saline) and lysed for 1 h on ice with lysis buffer
containing 1× PBS, 1% Triton X-100 and Complete. Cell lysates were
centrifuged to remove cell debris. Rabbit anti-human fibrinogen antibodies
(Dako, Zug, Switzerland), preadsorbed with magnetic polystyrene beads
covalently bound to recombinant protein G (Dynabeads Protein G; Dynal
Biotech, Oslo, Norway) at room temperature for 40 min, were added to cell
lysates and media and incubated for 1 h on ice. The beads were parted from the
buffer using a magnet, washed 3 times with lysis buffer and resuspended in
Laemmli buffer (62.5 mM Tris–HCl pH 6.8, 2% SDS, and 10% glycerol). The
immunoprecipitated proteins were released from protein G by boiling for 5 min
and were resolved by non-reducing 4% or 5% and reducing 7.5% SDS-PAGE,
according to Laemmli [19]. Gels were dried under vacuum at 80 °C for 20 min.
Labeled proteins were visualized by exposing gels over night to a storage
phosphor screen (Amersham Pharmacia Biotech, Uppsala, Sweden) and
analyzed using a Typhoon 9200 phosphor imager and the ImageQuant software
(Amersham Pharmacia Biotech). In order to verify the composition of a specific
band detected by autoradiography, the corresponding radioactive area was
excised from the dried gel and soaked, at room temperature, for 30 min in
0.125 M Tris–HCl, pH 6.8, containing 5% mercaptoethanol, 2% SDS, and 10%
glycerol. The gel slice was carefully placed on the top of an 8.5% gel, covered
with loading dye, and submitted to electrophoresis.
2.6. Western blot analysis
Western blot analysis on plasma was performed after resolving plasma
proteins by non-reducing 6% SDS-PAGE and electroblotting polyacrylamide
gels onto nitrocellulose membranes (Protran Nitrocellulose Transfer Membrane;
Whatman Schleicher and Schuell, Einbeck, Germany) over night at 100 mA by
means of a Biorad Trans-Blot Electrophoretic Transfer Cell (Biorad, Hercules,
CA, USA). Membranes were soaked in a blocking solution containing 5% skim
milk in TBST (10 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.1% Tween20) for 1 h
at room temperature and incubated with rabbit anti-human fibrinogen antibodies
(Dako) diluted 1:40,000 in blocking solution at room temperature for 2 h. For
control, non-specific rabbit purified IgG (Sigma, Saint Louis, MO, USA) were
also used as primary antibody (dilution 1:5,000). Membranes were washed 3
times for 10 min with TBST buffer and incubated for 1 h at room temperature
with secondary horseradish-peroxidase conjugated antibodies (Envision; Dako)
at a 1:5,000 dilution. After that, filters were washed 6 times for 5 min in TBS
supplemented with 0.3% Tween, 6 times for 5 min in TBST, and 2 times briefly
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nescence kit (SuperSignal West Dura; Pierce, Rockford, IL, USA) diluted 1:5,
according to the manufacturer's instructions.3. Results
3.1. Case report
The proband, a 34-year-old Italian male born in Rome from
non-consanguineous asymptomatic parents, suffered from fre-
quent post-traumatic hematomas during his life. Laboratory
analysis revealed unmeasurable levels of functional fibrinogen
(b5 mg/dL) and extremely reduced (1.43 mg/dL) immunoreac-
tive fibrinogen in plasma. Both parents showed low borderline
plasma antigen fibrinogen levels (182 and 161 mg/dL for the
father and the mother, respectively), while the proband's sister
had normal immunoreactive fibrinogen (232 mg/dL). Functional
fibrinogen levels measured in the proband's parents (father:Fig. 1. Pedigree of the analyzed afibrinogenemic family and identification of 1215
Functional and immunoreactive plasma fibrinogen levels (mg/dL), as well as the iden
arrow. (B) Strategies adopted to identify the 2 mutations. The top and the bottom pan
intron 3; exons are represented by boxes, introns by lines, and are not drawn to scale)
indicate the position of the 2 point mutations (1767TNG and 1215delT, respectively)
with the primer couple FGA-In2-F/FGA-In3-R. The middle panel shows electrophero
The position of the mutations (numbered according to GenBank, accession number161 mg/dL; mother: 171 mg/dL) confirmed the slight reduction
observed by ELISA (Fig. 1A).
3.2. Mutational screening
A previous mutational screening in this patient, performed
by sequencing the whole coding regions, the exon–intron
junctions and about 300 bp of the promoter regions of the FGA,
FGB, and FGG genes had identified a single heterozygous
mutation in FGA: 1215delT [18]. The same mutation was found
in the heterozygous state in both the patient's father and sister
(Fig. 1A). The second mutation contributing to the observed
phenotype was expected to be localized in the same gene but
could not be detected either by Southern blot analysis or by
long-range PCR amplification [18]. We then decided to extend
the mutational screening to the whole FGA sequence, seeking
for a “deep intronic”mutation or for a polymorphism preventing
stable annealing of 1 of the PCR primers used in the initialdelT and 1767TNG mutations in FGA. (A) Pedigree of the analyzed family.
tified mutations are reported below each symbol. The proband is indicated by an
els show a schematic representation of part of FGA (from the promoter region to
. The primers used to amplify exons 2 and 3 are indicated by arrows. M1 and M2
. The asterisk on allele 1 indicates the polymorphic site preventing amplification
grams of the region surrounding the identified mutations in the Aα-chain gene.
M64982) is indicated by an arrow. K denotes T or G nucleotides.
Fig. 2. Position of the Met51Arg mutation in the fibrinogen Aα-chain structure. (A) Ribbon diagram of human fibrinogen E domain and N-terminal portion of coiled-coil
regions, produced using the SwissPDB 3.7 software and the coordinates deposited under Protein Data Bank entry “2A45”. The position of Met51 in the Aα chain is
indicated. Themodel is oriented to best display the sites ofmutated residues. TheN- andC-terminal residues of each chain are also indicated. (B)Amino-acid sequence of the
N-terminal portion of the coiled-coil region (25 residues of each fibrinogen chain are reported). The 6 cysteines involved in the 3 interchain disulfide bonds responsible for
holding the molecule together (known as N-terminal disulfide ring) are boxed in gray. The Met51 residue is pointed by an arrowhead. (C)Multiple alignment of the first 25
residues of the fibrinogen Aα chain belonging to the coiled-coil region from several vertebrates. Protein sequences were obtained from Ensembl (www.ensembl.org) under
the accession numbers P02671 (H. sapiens), NP_034326 (M. musculus), P06399 (R. norvegicus), P02672 (B. taurus), ENSMODG00000001252 (M. domestica), P14448
(G. gallus), ENSXETG00000026093 (X. tropicalis), NP_001002039 (D. rerio), and NEWSINFRUG00000153940 (T. rubripes). Protein numbering omits the signal
peptide. The length of the signal peptides, when not available in the literature, has been predicted using the CBS (Center for Biological Sequence analysis) SignalP 3.0 Server
(http://www.cbs.dtu.dk/services/SignalP/). The arrowhead indicates the position of theMet51 residue. Conserved residues are shaded in grey, while identical amino acids are
in bold.
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mutated allele. To this purpose, all previously sequenced FGA
regions were newly amplified using different (exonic) primers
and inspected by direct sequencing. A novel heterozygous T to
G transversion, located in exon 3 of FGA at nucleotide position
1767 (numbering according to GenBank accession number
M64982) was identified (Fig. 1B). The same genetic alteration
was found in the patient's mother. Sequencing of the region
recognized by the forward primer used to amplify exon 3 (FGA-
In2-F, see Fig. 1B) in the first mutational screening, revealed
both the proband and his mother to be heterozygous for a T to C
variation (rs2070016). This nucleotide substitution corresponds
to the 3′ end of the FGA-In2-F primer, and is therefore likely to
prevent the amplification of FGA exon 3 (Fig. 1B).At the protein level, the 1767TNG substitution determines the
introduction of an arginine (AGG) instead of amethionine (ATG) at
codon 51 of the Aα chain (numbering omitting the signal peptide).
This residue is placed at the very beginning of the coiled-coil
domain (Fig. 2A), in a region that is predicted to play an important
role in the hexamer assembly [20]. Further supporting the possible
pathogenic role of Met51Arg, it should be noted that the involved
residue is located just downstream of the disulfide ring (Fig. 2B)
and lies in a region highly conserved among vertebrates (Fig. 2C).
3.3. Expression of wild-type and mutant fibrinogen molecules
To evaluate the effects of the Met51Arg substitution on
fibrinogen synthesis, assembly, stability, and secretion, wild-
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cells (not expressing fibrinogen). To this aim, the identified
mutation was inserted by site-directed mutagenesis in the
mammalian expression vector pRSV-Neo-Aα to obtain the
mutant construct pRSV-Neo-Aα-Met51Arg. COS-1 were then
transiently co-transfected with equimolar quantities of pRSV-
Neo-Bβ, pRSV-Neo-γ, and pRSV-Neo-Aα or pRSV-Neo-Aα-
Met51Arg to mimic the wild-type and the mutant conditions,
respectively. Moreover, considering that during the initial steps
of the fibrinogen assembly the only intermediate involving the
Aα chain is the Aα-γ heterodimer [21], a co-transfection
experiment with the pRSV-Neo-Aα and pRSV-Neo-γ plasmids
was also set up. As negative control, COS-1 cells were also
mock-transfected with the unrelated pUC18 plasmid. Trans-
fected cells were incubated with [35S]-methionine and [35S]-
cysteine for 2 and 16 h. Recombinant radiolabeled fibrinogen
molecules were immunoprecipitated from culture media and
cell lysates and resolved by non-reducing and reducing SDS-
PAGE. In cells transfected with the 3 wild-type fibrinogen
plasmids, the specific wild-type 340-kDa fibrinogen band was
present both in media and lysates after 2 (data not shown) and
16 h incubation (Fig. 3A, and B left panel). On the contrary, in
all samples from cells transfected with the pRSV-Neo-Aα-
Met51Arg the hexameric fibrinogen was undetectable, while a
smaller band of about 200 kDa, probably representing an
intermediate of fibrinogen assembly, was visible (Fig. 3A, andFig. 3. SDS-PAGE analysis of wild-type and Met51Arg mutant fibrinogens and Wes
(A) and conditioned media (B) of COS-1 cells transfected with equimolar mixtures o
construct. Cells were also transfected with the wild-type Aα and γ plasmids; mock tra
with [35S]-methionine and [35S]-cysteine. Samples were separated on 5% (panel A) a
7.5% SDS-PAGE (panel B, right) under reducing conditions. The boxed band (pane
conditions (panel C). (D)Western blot analysis of the plasma of the patient and of a he
reducing conditions. The patient's plasma was loaded as such, whereas the plasma o
200 mg/dL) was diluted 1:500. The lane “proband (IgG)” contains a control sample
replaced by a non-specific IgG. The trimeric fibrinogen band is indicated by an arroB left panel). The same samples run under reducing conditions
showed the expected pattern of bands corresponding to the 3
fibrinogen chains (Fig. 3B, right panel), suggesting that the 200-
kDa band could correspond to the trimeric fibrinogen half
molecule. To confirm this hypothesis, this band was excised from
the dried gel, placed in a soaking buffer (as described inMaterials
and methods), and eventually re-electrophoresed on a 8.5% SDS-
PAGE, under reducing conditions. As shown in Fig. 3C, 3 bands
were resolved with molecular weights compatible with the 3
fibrinogen chains, thus demonstrating that the 200-kDa band
corresponds to the trimeric fibrinogen. The additional specific
fibrinogen band of about 120 kDa detected in the lysates of cells
expressing either wild-type or mutant fibrinogen (Fig. 3A) likely
corresponds to Aα-γ dimers, as confirmed by its presence also in
cells expressing only Aα and γ chains.
3.4. Western blot analysis
In order to verify whether fibrinogen half molecules were
present also in the patient's plasma, Western blot analysis was
performed after non-reducing 6% SDS-PAGE. A 1:500 dilution
of the plasma of a wild-type individual with a normal amount of
immunoreactive fibrinogen (200 mg/dL) was used as a positive
control. While hexameric fibrinogen was detected both in the
patient's plasma and in the positive control, the trimeric
molecule was detected only in the patient's plasma (Fig. 3D).tern blot on the patient's plasma. Immunoprecipitated proteins from cell lysates
f wild-type Bβ and γ plasmids, together with the wild-type or the Met51Arg Aα
nsfected (pUC18) COS-1 cells represent the negative control. Cells were labeled
nd 4% (panel B, left) SDS-PAGE under non-reducing conditions, as well as on
l B, left) was excised from the gel, and run again on a 8.5% gel under reducing
althy control individual. Proteins were separated on a 6% SDS-PAGE under non-
f the healthy control individual (having an immunoreactive fibrinogen level of
in which the patient's plasma was loaded as such and the primary antibody was
whead.
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Only in 20% of the more than 300 cases of congenital
afibrinogenemia clinically described so far the causal mutations
have been identified. Most of them (95%) are point mutations
giving rise to null alleles originating from nonsense, small
insertions and deletions, and splicing mutations. The majority of
alterations (55%) appear to be clustered in the Aα-chain gene
[9]. Despite that, all of the missense mutations causing
quantitative fibrinogen deficiency (including both hypo- and
afibrinogenemia) are located in the Bβ- and γ-chain genes [9].
Very recently, a missense mutation was identified in the Aα-
chain gene in a case of hypofibrinogenemia, but its causal role
was not experimentally verified [22].
A previous study from our group in a 34-year-old Italian
afibrinogenemic proband born from non consanguineous
parents reported the identification of a heterozygous frameshift
mutation (1215delT) in FGA leading to the introduction of a
premature stop at codon 51 (FS51stop), preceded by an
abnormal sequence of 31 amino acids [18]. However, the
presence of a single mutant allele was not sufficient to explain
the severe phenotype of the patient, suggesting that a second
unidentified mutation affecting the same gene (FGA) was
missing [18]. Hence, we decided to screen for mutations the
entire FGA gene. The use of different primers during re-
sequencing allowed from one side the identification of the
Met51Arg mutation, and from the other side to find out why this
second mutation escaped the “conventional” mutational screen-
ing, i.e. the presence of a polymorphism (rs2070016) in the
annealing region of the FGA-In2-F PCR primer (Fig. 1B).
The newly identified Met51Arg mutation is a non-conserva-
tive amino-acid substitution affecting a residue located at the
very beginning of the fibrinogen coiled-coil domain (Fig. 2). The
Aα Met51 residue is located in the centre of an inter-subunit
hydrophobic core involvingAαPro46, AαLeu54,γIle25,γAla26,
and γLeu29. It makes van der Waals contacts with all these
hydrophobic residues. Moreover, the presence of an arginine at
position 51 could eletrostatically repulse Arg50, inducing a
conformational variation that could interfere with the dimeriza-
tion of 2 trimers.
Among the different pathways of fibrinogen assembly
proposed thus far [7,23], it is now accepted that the initial
assembly of fibrinogen goes through the formation of Aα-γ and
Bβ-γ heterodimers. The further addition of a third chain forms
AαBβγ half molecules that dimerize to form the mature protein
(AαBβγ)2 [21]. The 2 half molecules are joined not only by 3
symmetrical disulfide bonds (involving Aα Cys28, γ Cys8,
and γ Cys9) and by a disulfide link between Aα Cys36 and
Bβ Cys65 bridging the 2 half molecules, but also by the 2
disulfide rings delimiting each coiled-coil region [24]. It has
been demonstrated that deletions of the N-terminus and of the
first half of the coiled-coil region of the Aα chain, including also
the Met51 residue, do not impair the assembly both of Aα-γ and
Bβ-γ dimers, and of AαBβγ half molecules, but prevent half
molecules fromdimerization to give rise tomature fibrinogen [20].
Site-directed mutagenesis experiments were performed by Zhang
and colleagues [24] in order to disrupt the disulfide ring betweencysteines 45 and 49 of the Aα chain and the corresponding
counterparts in the γ (Cys23) and Bβ (Cys76) chains. Expression
of the obtained mutants demonstrated that these cysteines are not
involved in the Aα-γ e Bβ-γ heterodimers and AαBβγ half-
molecule formation, but they are essential to the hexamer assembly
process [24]. Therefore, it has been proposed that disruption of the
N-terminal disulfide ring causes theN-terminus of each chain to be
distorted, thus preventing the “docking” of the 2 half molecules,
and eventually the hexamer formation [24].
In this study, the pathogenic role of the Met51Arg mutation in
the fibrinogen Aα chain was explored by transient expression of
the Aα Arg51 fibrinogen in COS-1 cells. The obtained results
confirm the hypothesis put forward on the basis of the type and
position of the amino-acid substitution and of literature data. In
particular, the Met51Arg mutation does not seem to either affect
Aα chain synthesis or interfere with the assembly pathway, at
least up to the formation of AαBβγ trimers. In fact, trimeric
fibrinogen accumulated within cells expressing the mutant
molecule while mature fibrinogen was extremely reduced both
in cell lysates and in culture media (Fig. 3A and B). This suggests
that the mutation prevents half-molecules dimerization, probably
altering the formation of the disulfide bonds involving the nearby
Cys49 and Cys45, essential to this final step. The presence
intracellularly of similar amounts of Aα-γ heterodimers in cells
expressing wild-type and Aα Arg51 fibrinogen confirms that the
initial step in fibrinogen assembly involving the Aα chain is not
hampered by the mutation (Fig. 3A).
Trimeric fibrinogen was shown to be partially secreted in
culture media, in agreement with the data from Xu and
colleagues [20], who also found small amounts of mutant half
molecules to be secreted by cells expressing N-terminal deleted
Aα chains. Consistently with these ex-vivo results, Western blot
analysis performed on the proband's plasma confirmed the
presence in vivo of the trimeric molecule. Unexpectedly, given
the presence of a null allele (1215delT) on the other chro-
mosome, traces of the hexameric fibrinogen were also detected
in the patient's plasma, suggesting that small amounts of mature
molecules can still be released by hepatocytes. The discrepan-
cies between the ex-vivo and in-vivo data concerning the
presence of small amounts of hexameric Aα Arg51 fibrinogen
are difficult to explain. A tentative explanation may be the
existence of cell-specific differences in permissiveness for
fibrinogen half-molecule dimerization and secretion.
In conclusion, the elucidation of the pathogenic role of the
Met51Arg mutation provides the first experimental evidence that
missense mutations affecting the fibrinogen Aα chain can be
responsible for congenital afibrinogenemia and widens our
knowledge on the protein region and residues important for fi-
brinogen assembly.
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